Could an old drug give new hope for rare bone cancers?
NCT ID NCT07321912
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tests whether adding eflornithine (DFMO) to standard chemotherapy helps people with Ewing sarcoma or osteosarcoma live longer without their cancer returning. About 406 participants with different stages of these bone cancers will receive DFMO alongside their usual treatment. The goal is to see if this combination improves survival and disease control compared to past results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.